Think

Search This Blog

Reaching ‘Herd Immunity’ Is Unlikely in the U.S., Experts Now Believe

May 03, 2021

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

BY APOORVA MANDAVILLI | NYTimes Health | Disclosure

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

Comments

A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says

Results of a large clinical trial found the treatment did not work any better than a placebo. Pam Belluck | NYTimes Health | Disclosure

Patients Hate ‘Forever’ Drugs. Is Wegovy Different?

The new obesity drugs might be an exception to a chronic, deadly problem: the failure to stick with medication. Gina Kolata | NYTimes Health | Disclosure

Hospitals Must Get Written Patient Consent for Pelvic Exams, H.H.S. Says

In a letter to teaching hospitals, the federal health agency said that institutions could lose Medicare funding if they didn’t comply. Emma Goldberg | NYTimes Health | Disclosure

Sleep Apnea Reduced in People Who Took Weight-Loss Drug, Eli Lilly Reports

The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk’s Wegovy. Gina Kolata | NYTimes Health | Disclosure

Some Older Women Need Extra Breast Scans. Why Won’t Medicare Pay?

Mammography can miss tumors in women with dense breasts, so their doctors often include ultrasound or M.R.I. scans. Patients often wind up paying the bill. Roni Caryn Rabin | NYTimes Health | Disclosure

Reaching ‘Herd Immunity’ Is Unlikely in the U.S., Experts Now Believe

Comments

Post a Comment